CAMBRIDGE, Massachusetts, October 16, 2025 / Biotech Newswire / --

马萨诸塞州剑桥市，2025年10月16日 /生物技术新闻社/ --

Nanopath

纳米路径

, a point-of-care diagnostics company enabling high-quality molecular testing in minutes, today announced the addition of five experts to its leadership and executive team. These new leaders join Nanopath’s Co-Founders and Co-CEOs Amogha Tadimety & Alison Burklund.

一家即时诊断公司，能够在几分钟内实现高质量的分子检测，今天宣布在其领导和执行团队中新增五位专家。这些新领导者将加入Nanopath的联合创始人兼联席CEO阿莫加·塔迪米蒂和艾莉森·伯克伦德的行列。

“Not only are these individuals expert in their respective fields, they are also highly collaborative, fantastic leaders, and embody the mission and culture of the company”

“这些人不仅在各自领域非常专业，而且他们具有很高的协作性，是出色的领导者，体现了公司的使命和文化。”

said Alison Burklund, Ph.D., Co-Founder and Co-CEO at Nanopath.

伯克伦德博士说，她是Nanopath的联合创始人兼联合首席执行官。

Together, the team brings decades of experience across clinical medicine, product development, manufacturing, and commercialization.

团队成员在临床医学、产品开发、制造和商业化方面拥有数十年的经验。

Edward Evantash, MD: Chief Medical Officer

Edward Evantash，医学博士：首席医疗官

Dr. Evantash will lead Nanopath’s clinical strategy, bridging between science and patient care while also contributing to regulatory and market access strategy. He previously served as Medical Director and Vice President of Global Medical Affairs at Hologic for more than a decade, following his role as Division Chief of General Obstetrics and Gynecology at Tufts University School of Medicine.

埃万塔什博士将领导Nanopath的临床战略，在科学与患者护理之间架起桥梁，同时还将为监管和市场准入战略作出贡献。在加入Nanopath之前，他曾担任Hologic公司的医学总监及全球医学事务副总裁超过十年，更早之前则是塔夫茨大学医学院普通妇产科主任。

Dr. Evantash earned his medical degree from the University of Pennsylvania and completed his residency in Gynecology and Obstetrics at Johns Hopkins..

埃文塔什博士获得了宾夕法尼亚大学的医学学位，并在约翰霍普金斯大学完成了妇产科的住院医师培训。

“I’m incredibly excited to join team Nanopath! I’m confident that Nanopath’s platform will set a new standard of care – they’ve risen the bar to new heights. I’ve spoken to the leading KOLs in this space, and the enthusiasm for Nanopath’s clinical impact is unmatched,”

“我非常激动能够加入Nanopath团队！我坚信Nanopath的平台将树立护理的新标准——他们已经把标杆提升到了新的高度。我已经与该领域的领先关键意见领袖交流过，Nanopath在临床影响方面的热情是无与伦比的。”

said Dr. Evantash.

埃文塔什博士说。

Matthew Black, PhD: Chief Scientific Officer

马修·布莱克，博士：首席科学官

Dr. Black, who has led Nanopath’s Assay Development Team since 2023, has been promoted to Chief Scientific Officer. Since joining Nanopath, he has driven significant advances to the company’s platform, including generating industry-leading clinical data, decreasing time-to-result, and improving platform sensitivity more than 1,000-fold.

自2023年领导Nanopath的检测开发团队的布莱克博士已被提升为首席科学官。自加入Nanopath以来，他推动了公司平台的重大进展，包括生成行业领先的临床数据、缩短结果产出时间，并将平台灵敏度提高了1000多倍。

Previously, Dr. Black led the development of the first FDA-authorized at-home molecular test for COVID-19 at Lucira Health, guiding it from feasibility through commercialization. Dr. Black holds a Ph.D. in Chemical Engineering from the University of California, Santa Barbara..

此前，布莱克博士在卢西拉健康公司领导了首个获FDA授权的家用新冠分子测试的开发，引导其从可行性研究走向商业化。布莱克博士持有加州大学圣塔芭芭拉分校化学工程博士学位。

“I’m excited to take on this role and proud to work with such a passionate team that is redefining how we bring fast, accurate molecular testing closer to patients,'

“我为能担任这一角色感到兴奋，并为与这样一个充满热情的团队合作感到自豪，这个团队正在重新定义我们如何将快速、准确的分子检测带给患者。”

said Dr. Black.

布莱克博士说。

Matt Cote, ME: Vice President of Engineering

马特·科特，工程副总裁

Mr. Cote, who has led Nanopath’s Engineering Team since 2022, has been promoted to Vice President of Engineering. At Nanopath, he has implemented innovative, scalable hardware and software solutions for the company’s novel cartridge-reader system, advancing its performance, reliability and usability.

自2022年以来一直领导Nanopath工程团队的科特先生已被提升为工程副总裁。在Nanopath，他为公司的新型卡盒读取器系统实施了创新且可扩展的软硬件解决方案，提升了其性能、可靠性和可用性。

Mr. Cote brings experience from Quanterix, where he led an interdisciplinary team of engineers to advance single molecule protein detection technology. He holds a Master’s in Engineering from the University of Connecticut..

科特先生带来了他在Quanterix的工作经验，其间他带领一支由工程师组成的跨学科团队，推动了单分子蛋白质检测技术的发展。他拥有康涅狄格大学的工程学硕士学位。

Madeleine Livingston, MBA: Strategic Women’s Health Advisor

玛德琳·利文斯顿，工商管理硕士：战略女性健康顾问

Ms. Livingston will serve as an advisor focused on Nanopath’s women’s health strategy, partnership milestones, and opportunities to maximize the platform’s clinical impact. She brings experience mobilizing payers, employers, and industry to launch innovative programs that deliver measurable economic impact.

利文斯顿女士将担任顾问，专注于Nanopath的女性健康战略、合作伙伴里程碑以及最大化平台临床影响力的机会。她拥有调动支付方、雇主和行业资源以启动具有可衡量经济影响的创新项目的丰富经验。

Madeleine currently serves as the Director of Strategic Partnerships at Thirty Madison and has contributed to national and international initiatives through roles with the Gates Foundation’s Women’s Health Innovation Equity Forum. Ms. Livingston holds an MBA from The Tuck School of Business at Dartmouth..

玛德琳目前担任Thirty Madison的战略合作总监，并通过在盖茨基金会的女性健康创新公平论坛中的角色，为国家和国际倡议做出了贡献。利文斯顿女士拥有达特茅斯大学塔克商学院的工商管理硕士学位。

Christopher Slachta, PhD: Operations & Manufacturing Advisor

克里斯托弗·斯拉赫塔，博士：运营与制造顾问

Dr. Slachta will support Nanopath’s transition from development to production-scale manufacturing. He brings extensive experience from leadership roles at medical diagnostics companies. He is currently COO at Cytovale and previously held leadership roles in manufacturing and operations at Abbott and Ortho Clinical Diagnostics.

斯拉赫塔博士将支持Nanopath从开发阶段过渡到生产规模制造。他在医疗诊断公司担任领导职务方面拥有丰富的经验。他目前是Cytovale的首席运营官，并曾在雅培和奥森临床诊断公司担任生产和运营方面的领导职务。

Dr. Slachta holds a Ph.D. in Molecular Immunology and Microbiology from the Lewis Katz School of Medicine at Temple University..

斯拉赫塔博士拥有坦普尔大学刘易斯·卡茨医学院的分子免疫学和微生物学博士学位。

These leaders are joining at an exciting time for Nanopath. In the last year, the company has expanded from 13 to 20 employees and has achieved significant traction spanning product development, pilot clinical studies, and regulatory activities.

这些领导人加入Nanopath正值令人兴奋的时刻。在过去的一年里，公司从13名员工发展到20名，并且在产品开发、初步临床研究和监管活动方面取得了显著的进展。

“Our new leadership, together with our interdisciplinary team, will propel forward Nanopath’s mission to transform diagnostics for women’s health and beyond”

“我们的新领导层与跨学科团队将推动Nanopath的使命，变革女性健康及更多领域的诊断方式。”

said Amogha Tadimety, Ph.D., Co-Founder and Co-CEO at Nanopath.

Nanopath联合创始人兼联合首席执行官阿莫加·塔迪梅蒂博士说。

About

关于

Nanopath

纳米路径

Nanopath is a women-led company dedicated to improving health equity worldwide, starting with women's health. Nanopath's proprietary molecular diagnostic testing platform takes a radically new approach to how clinicians characterize human health. The company's novel biosensing technology has the potential to enable fast, high-complexity testing at the point-of-care, rather than in centralized laboratories.

Nanopath是一家由女性领导的公司，致力于改善全球健康公平性，首先从女性健康开始。Nanopath专有的分子诊断测试平台对临床医生如何描述人类健康采取了全新的方法。该公司的新型生物传感技术有可能在护理点实现快速、高复杂性的测试，而不是在集中式实验室中进行。

The company is headquartered in Cambridge, Mass., at The Engine built by MIT, a premier facility for high-potential, tough-tech start-ups. Nanopath is backed by Norwest Venture Partners, the Medtech Convergence Fund, Gingerbread Capital and Green D Ventures. .

公司总部位于马萨诸塞州剑桥市，设在麻省理工学院创建的The Engine，这里是高潜力、高难度技术初创公司的顶级设施。Nanopath得到了Norwest Venture Partners、Medtech Convergence Fund、Gingerbread Capital和Green D Ventures的支持。

Contact

联系

Nanopath

纳米路径

Alison Burklund

艾莉森·伯克兰

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Keywords: Nanopath; leadership expansion; executive team; point-of-care diagnostics; molecular testing; rapid testing; Amogha Tadimety; Alison Burklund; Edward Evantash; Matthew Black; Matt Cote; Madeleine Livingston; Christopher Slachta; women-led company; women’s health; molecular diagnostic testing; proprietary technology; biosensing technology; point-of-care testing; decentralized diagnostics; fast molecular testing; Cambridge, Massachusetts.

关键词：Nanopath；领导力扩展；执行团队；即时诊断；分子检测；快速检测；Amogha Tadimety；Alison Burklund；Edward Evantash；Matthew Black；Matt Cote；Madeleine Livingston；Christopher Slachta；女性领导的公司；女性健康；分子诊断测试；专有技术；生物传感技术；即时检测；分散式诊断；快速分子检测；马萨诸塞州剑桥。

Source: Biotech Newswire

来源：生物技术新闻专线